The stock of Biomerica, Inc. (NASDAQ:BMRA) is a huge mover today! The stock increased 10.34% or $0.27 on October 3, hitting $2.88. About 52,238 shares traded hands or 430.77% up from the average. Biomerica, Inc. (NASDAQ:BMRA) has declined 99.05% since February 29, 2016 and is downtrending. It has underperformed by 111.27% the S&P500.
The move comes after 8 months positive chart setup for the $22.13 million company. It was reported on Oct, 3 by Barchart.com. We have $4.03 PT which if reached, will make NASDAQ:BMRA worth $8.85 million more.
According to Zacks Investment Research, “BIOMERICA, INC. is an emerging-growth biotechnology firm that develops, manufactures and distributes medical diagnostic products. The Company is focused on niche products for early detection and monitoring of human diseases and conditions before they become catastrophic and incurable. The customers include medical universities, pharmaceutical companies, hospitals, clinics, commercial laboratories, physician’s offices and consumers.”
More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: Quotes.Wsj.com which released: “Biomerica Inc. BMRA (US: Nasdaq)” on February 27, 2011, also Streetinsider.com with their article: “Biomerica, Inc. (BMRA) Cleared to List on Nasdaq CM” published on August 24, 2016, Seekingalpha.com published: “Biomerica: The Next Major IBS Product” on September 01, 2016. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: Marketwired.com and their article: “Biomerica Reports First Quarter Results” published on October 16, 2014 as well as Finance.Yahoo.com‘s news article titled: “Biomerica to Present at 18th Annual Rodman & Renshaw Global Investment Conference” with publication date: September 06, 2016.
BMRA Company Profile
Biomerica, Inc., incorporated on September 22, 1971, is a biomedical company, which develops, makes and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores). The Firm operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company’s diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.